메뉴 건너뛰기




Volumn 17, Issue 9, 2008, Pages 882-889

Identifying patterns of adverse event reporting for four members of the angiotensin II receptor blockers class of drugs: Revisiting the Weber effect

Author keywords

Adverse event reporting; Angiotensin II receptor blockers; Food and drug administration; Weber effect

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; CANDESARTAN; IRBESARTAN; LOSARTAN; VALSARTAN;

EID: 52949152357     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.1633     Document Type: Article
Times cited : (41)

References (10)
  • 1
    • 84889452671 scopus 로고    scopus 로고
    • Spontaneous reporting in the United States
    • 4th edn, Strom BL ed, John Wiley & Sons: New York, NY
    • Ahmad SR, Goetsch RA, Marks NS. Spontaneous reporting in the United States. In Pharmacoepidemiology, (4th edn), Strom BL (ed.). John Wiley & Sons: New York, NY, 2005; 135-159.
    • (2005) Pharmacoepidemiology , pp. 135-159
    • Ahmad, S.R.1    Goetsch, R.A.2    Marks, N.S.3
  • 2
    • 52949138045 scopus 로고    scopus 로고
    • Title 21 of the Code of Federal Regulations, Subpart 314.80. Additionally, 21 CFR 310.305 and 21 CFR 314.98.
    • Title 21 of the Code of Federal Regulations, Subpart 314.80. Additionally, 21 CFR 310.305 and 21 CFR 314.98.
  • 3
    • 0002656565 scopus 로고
    • Epidemiology of adverse reactions to nonsteroidal anti-inflammatory drugs
    • Rainsford KD, Velo GP eds, Raven Press: New York, NY
    • Weber JCP. Epidemiology of adverse reactions to nonsteroidal anti-inflammatory drugs. In Advances in Inflammation Research, Rainsford KD, Velo GP (eds). Raven Press: New York, NY, 1984; 1-7.
    • (1984) Advances in Inflammation Research , pp. 1-7
    • Weber, J.C.P.1
  • 4
    • 0035083642 scopus 로고    scopus 로고
    • Temporal patterns of NSAID spontaneous adverse event reports: The Weber effect revisited
    • Wallenstein EJ, Fife D. Temporal patterns of NSAID spontaneous adverse event reports: the Weber effect revisited. Drug Saf 2001; 24: 233-237.
    • (2001) Drug Saf , vol.24 , pp. 233-237
    • Wallenstein, E.J.1    Fife, D.2
  • 5
    • 2942554869 scopus 로고    scopus 로고
    • Replication of the Weber effect using postmarketing adverse event reports voluntarily submitted to the United States Food and Drug Administration
    • DOI: 10.1592/phco.24.9.743.36068
    • Hartnell NR, Wilson JP. Replication of the Weber effect using postmarketing adverse event reports voluntarily submitted to the United States Food and Drug Administration. Pharmacotherapy 2004; 24; 743-749. DOI: 10.1592/phco.24.9.743.36068
    • (2004) Pharmacotherapy , vol.24 , pp. 743-749
    • Hartnell, N.R.1    Wilson, J.P.2
  • 6
    • 0141557914 scopus 로고    scopus 로고
    • Adverse event reporting with selective serotonin-reuptake inhibitors
    • DOI: 10.1345/aph.1C522
    • Hartnell NR, Wilson JP, Patel NC, et al. Adverse event reporting with selective serotonin-reuptake inhibitors. Ann Pharmacother 2003; 37: 1387-1391. DOI: 10.1345/aph.1C522
    • (2003) Ann Pharmacother , vol.37 , pp. 1387-1391
    • Hartnell, N.R.1    Wilson, J.P.2    Patel, N.C.3
  • 7
    • 0032877186 scopus 로고    scopus 로고
    • Comparative safety and tolerability of angiotensin II receptor antagonists
    • Mazzolai L, Burnier M. Comparative safety and tolerability of angiotensin II receptor antagonists. Drug Saf 1999; 21: 23-33.
    • (1999) Drug Saf , vol.21 , pp. 23-33
    • Mazzolai, L.1    Burnier, M.2
  • 8
    • 52949126514 scopus 로고    scopus 로고
    • Title 21 of the Code of Federal Regulations, Subpart 314.80
    • Title 21 of the Code of Federal Regulations, Subpart 314.80.
  • 9
    • 52949105511 scopus 로고    scopus 로고
    • Title 21 of the Code of Federal Regulations, Subpart 314.90
    • Title 21 of the Code of Federal Regulations, Subpart 314.90.
  • 10
    • 52949139219 scopus 로고    scopus 로고
    • Food and Drug Administration. Center for Drug Evaluation and Research, Office of Drug Safety. Annual Report FY 2004. http://www.fda.gov/cder/ Offices/ODS/AnnRep2004/default.htm#_Toc66679476 (Accessed 8 August 2007).
    • Food and Drug Administration. Center for Drug Evaluation and Research, Office of Drug Safety. Annual Report FY 2004. http://www.fda.gov/cder/ Offices/ODS/AnnRep2004/default.htm#_Toc66679476 (Accessed 8 August 2007).


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.